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Abstract 
Background: Glioblastoma (GBM) is a highly aggressive brain tumor with rapid subclonal 
diversification, harboring molecular abnormalities that vary temporo-spatially, a contributor to 
therapy resistance. Fluorescence guided neurosurgical resection utilizes administration of 5-
aminolevulinic acid (5ALA) generating individually fluorescent t mor cells within a background 
population of non-neoplastic cells in the invasive tumor region. The aim of the study was to 
specifically isolate and interrogate the invasive GBM cell population using a novel 5ALA based 
method.  
Methods: We have isolated the critical invasive GBM cell population by developing 5ALA-based 
metabolic fluorescence activated cell sorting. This allows purification and study of  invasive cells 
from GBM without an overwhelming background “normal brain” signal to confound data. The 
population was studied using RNAseq, rtPCR and immunohistochemistry, with gene targets 
functionally interrogated on proliferation and migration assays using siRNA knockdown and known 
drug inhibitors. 
Results: RNAseq analysis identifies specific genes such as SERPINE1 which is highly expressed in 
invasive GBM cells but at low levels in the surrounding normal brain parenchyma. siRNA 
knockdown and pharmacological inhibition with specific inhibitors of SERPINE1 reduced the 
capacity of GBM cells to invade in an in vitro assay. Rodent xenografts of 5ALA positive cells were 
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established and serially transplanted, confirming tumorigenicity of the fluorescent patient derived 
cells but not the 5ALA negative cells.  
Conclusions: Identification of unique molecular features in the invasive GBM population offer hope 
for developing more efficacious targeted therapies compared to targeting the tumor core and for 
isolating tumor sub-populations based upon intrinsic metabolic properties. 
 
Keywords: Glioblastoma; 5-aminolevulinic acid; Neurosurgery; Gene expression; Heterogeneity 
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Key Points:  
 Clinical 5ALA fluorescence can be used to isolate invasive GBM cells from normal 
brain parenchyma 
 Invasive GBM cells have unique molecular targets compared to cells from the bulk 
tumor  
 These unique invasive targets are potentially targetable to limit invasion by GBM 
 
Importance of the Study –  
Targeted therapy for glioblastoma (GBM) is complicated by intra-tumor heterogeneity, with most 
attempts to treat post-surgical residual disease based on extrapolation of from targets identified in the 
tumor core. Attempts to analyse invasive disease have been complicated by an overwhelming normal 
brain signal. This study uses 5 aminolevulinic acid to facilitate isolation of invasive GBM cells and 
interrogate them with RNAseq. We demonstrate novel molecular targets unique to the invasive 
population and the tumorigenicity of the 5ALA positive cells. We show how targeting SERPINE1 
with siRNA or pharmacological inhibitors can reduce the capacity of GBM cells to invade, giving 
hope that 5ALA based isolation may become a basis for identifying clinically relevant molecular 
targets on invasive GBM cells. 
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Introduction 
Overall survival for the high-grade malignant brain tumor glioblastoma (GBM) has remained 
disappointingly static over the last decade with a median survival of 14.6 months in patients treated 
radically with surgery, radiotherapy and temozolomide
1
. Multiple phase III trials of targeted agents 
based on biological data have failed to show any overall survival benefit
2-4
. The reasons for these 
setbacks are complex, including potential failure to achieve sufficient concentration of agents in the 
tumor microenvironment, but tumor heterogeneity (both inter and intra) and hence failure to target 
optimal molecular candidates is also contributory
5
. Heterogeneity in GBM is well established and 
variation in subclonal gene expression across tumors has been described, with truncal and discrete 
events developing during the spatio-temporal evolution of these tumors
6-8
. It is now recognized that a 
single biopsy specimen cannot inform the broad molecular landscape of a GBM.  
Tumor removed from the resection margin, where the GBM blends into and invades normal brain, has 
been suggested to exhibit different genetic profiles to tumor removed from the hypoxic core or viable 
enhancing rim regions as defined on gadolinium contrast enhanced MRI
9
. Recurrence in GBM 
predominantly occurs in this invasive zone within 2cm of the resection edge after surgery
10
 and it is 
logical that tumor genetic profiles from this region are more likely to identify molecular targets to 
delay recurrence. However, biopsies taken from the invasive zone will contain substantial amounts of 
non-neoplastic cells, including immune infiltrates and normal CNS cells, which may dominate 
attempts at genome wide analysis of the tumor component and tumor signatures of invasion
11
. 
A phase III randomized clinical trial has demonstrated an increase in rates of complete resection of 
enhancing disease from 36% to 65% of GBM patients by the use of 5-aminolevulinic acid (5ALA) as 
a surgical adjunct
12
. 5ALA is a porphyrin, metabolized by cells where the heme synthesis pathway is 
active (e.g. GBM cells, but not non-neoplastic CNS cells), to the fluorescent metabolite 
protoporphyrin IX (PpIX) (Figure 1).  
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PpIX subsequently undergoes intracellular accumulation in GBM cells owing to their lack of 
ferrocheletase activity, with maximal excitement induced by blue light at 400-410nm and the main 
emission light peaks at 635nm and 704nm (pink) (Figure 1).  
Areas of pink fluorescence as observed by the operating surgeon correspond to areas of high viable 
tumor cell density and are a suitable target for resection
13
. The necrotic core does not fluoresce due to 
the lack of viable cellular metabolism, and at the peripheral invasive edge of visible tumor, the pink 
fluorescence fades to blue as the tumor cell density falls. Although non- or weakly-fluorescent, this 
region has been shown to still contain detectable numbers of invading GBM cells
13,14
. On an 
individual cell basis, GBM cells in the peripheral tumor still accumulate PpIX and hence fluoresce 
even in the absence of fluorescence perceptible to the human eye
15
 and we have sought to use this 
characteristic to isolate GBM cells from the invasive region from amongst the non-neoplastic 
parenchyma. 
In this study 58 regions from 11 patients undergoing surgery for MRI suspected GBM were taken 
from core areas (central 5ALA non-fluorescent regions), rim areas (5ALA fluorescent areas 
corresponding to gadolinium enhancing areas) and the invasive zone (5ALA weakly fluorescent, 
corresponding to non-enhancing areas beyond the rim of gadolinium uptake). A portion of the 
invasive zone sample was separated into 5ALA positive and 5ALA negative cells by fluorescence 
activated cell sorting (FACS). This is the first oncological study to metabolically isolate and purify 
GBM cells representative of infiltrative residual disease, from which candidate therapy targets are 
likely more clinically relevant and presents a methodological approach broadly applicable for solid 
cancers amenable to 5ALA induced metabolic labelling such as melanoma or breast cancer
16,17
. We 
report on the RNAseq data acquired from these different tumor areas and validate a novel potential 
therapeutic target found on the invasive zone 5ALA positive cells. 
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Materials and Methods 
Patient information 
This study included 11 (RNAseq) and 3 (gene expression array) newly diagnosed treatment naïve 
patients diagnosed with operable, likely high-grade glioma on diagnostic and advanced MRI 
sequences. One further patient underwent RNAseq analysis of 9 samples (core/rim/invasive regions 
each with unsorted/5ALA positive/5ALA negative samples). All patients were operated on by a single 
surgeon at a major regional Neuroscience center, with specimens collected after informed consent was 
obtained for this purpose from the patients and under ethics committee approval (11/EM/0076).  
Surgical sampling 
5ALA was administered orally to patients 2-4 hours prior to surgery at 20mg/kg dose. All patients 
underwent craniotomy with intra-operative image guidance and visualization of 5ALA induced 
fluorescence using an appropriately equipped operative microscope (Leica OH-X). Multi-region 
sampling was conducted, and sample location determined using image guidance. Samples were taken 
from non-fluorescent or minimally fluorescent tumor core (corresponding to T1 with gadolinium non-
enhancing or heterogeneously enhancing central tumor), viable fluorescent tumor rim (corresponding 
to peripheral strongly gadolinium enhanced areas on T1 MRI) and from the areas of 5ALA induced 
fluorescence furthest into the area of MRI T2 high signal beyond the bulk tumor, where tumor 
blended into brain in an invasive fashion (non-enhancing on T1 with gadolinium) (Figure 1D). 
Histological diagnosis of glioblastoma was confirmed by intra-operative smear and formal post-
operative diagnosis (including IDH mutations, ATRX mutation and MGMT methylation status) by the 
regional brain tumor neuropathology service (Supplementary Table 1). 
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Fluorescence Activated Cell Sorting (FACS) 
Cells were sorted using the MoFlo XPD sorter (Beckman Coulter) with excitation at 405 nm 
and emission detection at 605 – 625 nm. For increased purity, cells were sorted twice 
consecutively. U251 GBM cells incubated for 2 hours with and without 5-ALA were used as 
controls to set gates for sorting. The positive and negative sorted cells were centrifuged at 
800 rpm (180×g) for 5 minutes at room temperature and cell pellets snap frozen.  
Cell lines and primary cultures  
All cell lines used in this project (Supplementary Table 2), except C17.2, were of human origin. C17.2 
cells are multipotent neuronal stem cells derived from mouse cerebellum. U251 cells (confirmed on 
STR genotyping; Supplementary Figure 1), isolated from the core of a GBM tumor and sourced 
commercially, were used as a biological positive control for GBM cells. The Glioma INvasive margin 
(GIN) cell lines, isolated from the tumor infiltrative edge, were derived in-house from surgeries at the 
Queen‟s Medical Centre, Nottingham (comparable to their respective primary tissue on STR; 
Supplementary Figure 1). 
Other methods 
Full description of methods is provided in supplementary methods but in brief, cell culture was 
undertaken with/without 1ml 20mM 5ALA (Sigma-Aldrich, St. Louis, Missouri, USA) per 75ml 
flask. Presto blue (Invitrogen, USA) was performed to manufacturer‟s protocol. rtPCR was performed 
with iQ
TM
 SYBR® Green Supermix 2x (Bio-Rad) and immunohistochemistry with DAKO (Ely, UK) 
reagents and secondary antibody. Transcriptomic libraries were prepared using the NEBNext Poly(A) 
mRNA Magnetic Isolation Module (NEB: E7490), the NEBNext Ultra Directional Library Kit for 
Illumina (NEB: E7420) and the NEBNext Multiplex Oligos for Illumina (Index Primers Set 1) (NEB: 
E7335L). Raw data has been deposited at ArrayExpress, accession number E-MTAB-8743. siRNA 
knockdown was performed using 25nM of SERPINE1 targeting and non-targeting sequences 
(Dharmacon). Invasion assays were conducted using 24 well ThinCert
TM
 cell culture inserts (Greiner) 
coated with 10 µg of collagen IV (Cultrex, Trevigen). In vivo patient derived xenografts were 
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performed in male Rag2/Il2rg (RAG) immunodeficient mice (10-12 weeks old) according to NCRI 
and LASA guidelines. 
 
Results 
Patient Demographics 
The RNAseq patient cohort (n=11) (Supplementary Table 1) had a median age of 58.7 years and 
consisted of 5 males and 6 females. All patients had neuropathologically confirmed GBM with 
expression of wild type isocitrate dehydrogenase 1 (IDH-1) and wild type ATRX and underwent 
resection of their tumor with 5ALA guidance. All patients had multi-region sampling successfully 
performed to obtain samples from core, rim and invasive tumor regions. Eight patients received 60Gy 
radiotherapy in 30 fractions with concomitant and adjuvant temozolomide, two patients received a 
radiotherapy regime only and one patient received best supportive care (patient choice). Median 
survival was 15.0 months. 
 
In vitro optimization of 5ALA FACS parameters 
5ALA was applied to established cell lines and primary low passage GBM cultures (Glioma INvasive 
lines – GIN) and the percentage of positive fluorescent cells assessed using bright field and 
fluorescent microscopy (Figure 2 A-D).  
The percentage of 5ALA induced fluorescent cells was 84.2% (+/- 6.8%) in U251 commercial GBM 
cells and ranged from 83.6% (+/- 5.1%) to 78.8% in primary low passage GIN cell lines. One cell line 
derived from a recurrent GBM showed auto-fluorescence (44.4% of cells) but all other cell lines 
derived from primary resections had <5% fluorescence when studied without 5ALA(p=<0.05). The 
neural stem cell line C17.2 (after differentiation) demonstrated 1.5% (+/- 0.9%) fluorescent cells with 
5ALA and 0% fluorescence without 5ALA, significantly fewer than the actively dividing tumor cell 
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lines (t-test p value=<0.001). Similar results were obtained with the H1 human neural stem cell line, 
which exhibited fluorescence in its undifferentiated stem cell state but markedly reduced fluorescence 
after differentiation to post-mitotic astrocytes (p=<0.01) (Figure 2 E-H). Stem cell lines post-
differentiation demonstrated no difference between fluorescence levels in 5ALA exposed and 
untreated cells (p=>0.05). 
Scatter graphs of FACS data were created for each 5ALA positive and negative sample from each cell 
line with the x-axis representing size and the side scatter on the y-axis representing granularity. A gate 
was created based on a U251 sample and applied to the remaining samples. The cells within the gate 
were analyzed, using the FL11 channel to identify fluorescence levels. Fluorescence intensity levels 
varied within tumor cell populations, whether exposed to 5ALA or not, but clear separation between 
5ALA positive and negative cells were apparent (Figure 2I). Percentage of cells demonstrating high 
levels of fluorescence on FACS after application of 5ALA to each cell line was highly concordant 
with bright field microscopy (R
2
 = 0.98 and p = <0.001) (Supplementary Figure 2a). Gating and 
separation of cells into fluorescence positive and negative populations was performed using FACS via 
a two-stage process involving enrichment of the 5ALA positive population, followed by purification 
of the enriched population (Figure 2 J-L). No significant cell viability differences were observed 
between 5ALA exposed and unexposed cells for any cell lines (all t test p-values > 
0.05)(Supplementary Figure 2). 
 
Isolation and RNAseq analysis of different tumor regions  
Using FACS and gating methodology based on in vitro parameters, we proceeded to optimize the 
5ALA fluorescence method on surgically resected GBM as a test-bed before applying the 
methodology to the experimental patient cohort. We were successful in gating a 5ALA fluorescent 
population of cells that ranged from 0.72% to 9.6% of the total cell population in the invasive zone 
samples, with a mean of 1.52% (+/- 0.22%) (Supplementary Figure 2). Median time from sample 
resection to end of FACS process was 146 minutes, enabling utilization of the persistent 5ALA 
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fluorescence post-surgery. RNAseq analysis on individual regions demonstrated significant 
differences between unsorted tumor regions (core, rim and invasive). A median read of 106.8 million 
reads was achieved per unsorted sample, median 69.7 million reads per FACS sorted sample and with 
5 samples excluded due to poor read quality. 2567 genes were significantly differentially expressed 
between core tumor and unsorted invasive region samples (full gene list in Dataset 1) with clear 
separation of different microenvironmental regions when analyzed as a heatmap for significantly 
differentially expressed genes (Figure 3A), with pathway analysis suggesting many of these were, as 
would be predicted, associated with normal brain, an obstacle which has historically obscured GBM 
invasive region biological information.  
Many over-represented signaling pathways (Supplementary Table 3) in the group of genes 
upregulated in invasive regions were associated with synaptic activity and other CNS processes (e.g. 
neuroactive ligand-receptor interaction, GABAergic synapses, glutaminergic synapses and 
serotonergic synapses). 
 
Comparison of 5ALA/FACS positive and negative invasive cell populations by RNAseq analysis 
Comparison was made by RNAseq between 5ALA positive and negative cells isolated from the GBM 
tumor invasive margin. Sufficient good quality reads to allow comparison were obtained for 6 5ALA 
positive and 7 5ALA negative tumor regions. 78 genes were significantly differentially expressed 
with separation of fluorescent and non-fluorescent cell populations on a heatmap (Figure 3B) of the 
differentially expressed genes. Pathway analysis revealed significant enrichment for pathways 
associated with cellular motility and invasion, with enrichment for immune responses in addition 
(Supplementary Table 4 with full gene list in Supplementary Table 5). 78 genes were significantly 
upregulated between 5ALA/FACS positive cells and the unsorted invasive region, with 102 genes 
significantly down regulated. Similar differences were observed between 5ALA positive cells and 
both core and rim regions, with the greatest number of genes differing between 5ALA positive 
invasive cells and unsorted tumor core regions (Figure 3D). The 79 genes (50 upregulated and 29 
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down regulated) that were significantly different between 5ALA positive cells and all unsorted 
regions are listed as supplementary table 9. The high number of differentially expressed genes 
underscores the dissimilarities between 5ALA positive invasive cells and tissues from the GBM core 
region, which have been historically the basis of the majority of genomic studies to date based on the 
sampling strategies described where samples are only utilized if composed of very high tumor cell 
purity. Cross-comparison of the differentially expressed genes between the different regions showed 
that only 9.1% of differentially expressed genes were conserved among the three regions, indicating a 
high degree of GBM intra-tumor heterogeneity based upon RNAseq expression levels.  Pathway 
analysis showed significant differences in extracellular matrix (ECM) organization and metabolic 
processes (Supplementary Table 6).  
To test the overlap between 395 upregulated genes in 5ALA/FACS po itive invasive cells and the 
genotypic classifier developed by Verhaak et al.
18
 we used the GeneOverlap R package and Fisher‟s 
exact test. There was significant enrichment for the mesenchymal subgroup gene signature (37 of 216 
GBM mesenchymal associated genes) but not for other GBM subgroup gene signatures (p = <0.001 
Fisher‟s exact test), suggesting the invasive cells carry a predominantly mesenchymal genotype. Key 
oncogenes showed differing expression profiles depending on which region of the tumor was 
analyzed, with lower expression of SOX2 or elevated expression of SERPINE1 and MMP19 (Figure 
3E) in 5ALA/FACS positive cells for example. For other markers e.g. OLIG2 there were no 
significant differences between 5ALA positive cells and unsorted cell populations. All invasive area 
cells (mixed unsorted, 5ALA negative and 5ALA positive) showed low expression levels of VEGFA 
compared to tumor core and rim regions (Figure 3E). 5ALA/FACS positive cells were generally 
enriched for inflammatory response genes and anti-apoptotic genes, with comparative down 
regulation of hypoxia response and angiogenic genes on pathway analysis. Overall 
immunophenoscores (Supplementary Figure 3 E&F) were similar between regions but expression of 
some conventional immune targets such as PDL1 was found to be higher in the core but importantly, 
with no elevation in 5ALA positive invasive cells (Figure 4D). 
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For one further additional GBM patient 5ALA sorting and RNAseq analysis was performed for all 3 
regions (core, rim and invasive areas). Global correlation comparison was made for the RNAseq 
expression signatures between the different unsorted regions of the same tumor and 5ALA/FACS 
positive and negative cells from the respective region. 5ALA negative cells isolated from the invasive 
margin were extremely similar to the unsorted population from this region (R=0.99), whereas 5ALA 
positive cells isolated from the invasive margin showed clearer differences (R=0.83) (Supplementary 
Table 7). 5ALA/FACS negative cells isolated from the tumor core were also similar to the unsorted 
tumor core population, possibly due to these representing tumor cells unable to metabolize 5ALA to 
the fluorescent product due to the hypoxic conditions within this central tumor region. 
Validation real time PCR studies were undertaken for 4 genes, all of which demonstrated fold changes 
in the same direction and similar magnitude between 5ALA positive and negative cells to those 
suggested by the RNAseq study (Supplementary Figure 3 A-C). We chose to focus on genes with high 
differential expression between 5ALA positive and negative cells, and included VEGFa as a 
recognized therapeutic target. 
 
Gene Expression Array Analysis 
To cross-validate RNAseq data and gain further insight into the molecular characteristics of the GBM 
invasive region and its relationships to other intra-tumor regions, we used microarray profiling to 
derive gene expression signatures representative of the invasive-enriched populations using freshly 
sorted cells from invasive regions prospectively from three additional GBM patients (Supplementary 
Table 1). Hierarchical clustering based on conserved genes again showed distinct clustering of the 
GBM samples from different regions. Significant differences in expression were also visualized 
between FACS isolated fluorescence positive and unsorted cells (Figure 3C). Comparison between the 
RNAseq dataset and the independent gene expression array dataset showed 61 genes with 
significantly different expression between 5ALA positive and negative cells and fold change in same 
direction in both transcriptomic studies (Supplementary Table 8). Gene ontology (GO) enrichment 
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analysis showed that the 5ALA positive cells were enriched for GO categories related to 
inflammatory response, immune response, response to lipopolysaccharide, anti-apoptosis, inactivation 
of MAPK activity, positive regulation of cell division, and negative regulation of cell proliferation. 
The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis attributed up-regulated 
genes to several signaling pathways such as MAPK, NOD-like receptor, Chemokine signaling, Toll-
like receptor, and Cytosolic DNA-sensing, consistent with the observed GO categories. In contrast, 
down-regulated pathways in 5ALA positive cells were significantly enriched for the GO categories of 
response to hypoxia, cell adhesion, angiogenesis, and cell differentiation; and for the KEGG pathways 
of ECM-receptor interaction, Pathways in cancer, Focal adhesion, and Protein digestion and 
absorption. Many genes linked to cellular invasion were identified as having unique expression 
profiles in 5ALA/FACS positive invasive cells on both RNAseq and on the gene expression 
microarray, such as DUSP family genes, EREG and KLF4 (all upregulated relative to core, rim and 
invasive tissue regions). Other genes linked to immune modulation were upregulated by the 
5ALA/FACS positive invasive population, e.g. IL1A (Figure 4A).  
Pathway analysis of differentially expressed genes showed significant enrichment for pathways such 
as cell migration, ECM organization and peptidase activity, suggesting that the 5ALA positive 
population represents a molecular snapshot of true invasive GBM components (Supplementary Figure 
4) when isolated as a minority population from the infiltrative edge of the tumor.  
 
Analysis of the impact of FACS processing of samples 
We wished to exclude any confounding effect by the FACS process on true in situ gene expression 
signatures. Therefore, for one additional patient, FACS based on 5-ALA fluorescence was conducted 
on all regions of the tumor (core, rim and invasive area) and RNAseq analysis performed. Comparison 
was then made to unsorted cells to establish whether any systematic changes in patterns of gene 
expression were attributable to the process of dissociation of tumor tissue and FACS. Systematic 
changes due to FACS were only detected for a small number of genes, known to be stress response 
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genes, indicating an effect for certain genes such as TNF-α (Supplementary Figure 3D). Crucially, no 
FACS-induced effect was evident for the genes identified as differentially expressed and involved in 
migratory or ECM modification pathways. TNF-α was consistently overexpressed in all cells that had 
undergone FACS but interestingly was expressed at higher levels in 5ALA positive cells compared to 
5ALA negative, perhaps indicating a differing stress response between tumor and non-tumor cells. 
 
Immunohistochemical validation 
Selected differentially expressed genes were also examined for expression at the protein level by 
immunohistochemistry. Results replicated the RNAseq findings with decreased expression of VEGF-
A and increased expression of SERPINE1 in tumor core tissue relative to tumor invasive margin 
tissue (Figure 4 B/C and E/F) with scoring in Supplementary Figure 5 A&B. However, individual 
SERPINE1 positive cells in the invasive margin may correspond to the 5ALA positive tumor sub-
population expressing SERPINE1 at a high level (Figure 4 F), but existing as a minority population 
within the total unsorted tissue sample, with a predominance of low/absent SERPINE1 expression in 
normal brain harboring these invasive GBM cells. 
 
The effect of SERPINE1 on proliferation and invasion 
Validation of the functional effects of genes identified as associated with the infiltrative phenotype of 
invasive GBM cells was undertaken, using SERPINE1 as an example of a candidate gene consistently 
upregulated in 5ALA/FACS positive cells from the invasive region compared to the unsorted mixed 
population from the invasive regions (t test p=0.006) and 5ALA/FACS negative cell populations (t 
test p=0.014) (Figure 4G). Transient siRNA knockdown of the SERPINE1 gene was undertaken and 
the effect on cellular proliferation assessed. We found no significant difference between 
untransfected, control (scrambled) siRNA and SERPINE1 specific siRNA in terms of cellular growth 
and proliferation of GBM cells in vitro (Supplementary Figure 5 C&D). Using a transwell collagen 
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barrier assay we then proceeded to assess the effect of SERPINE1 knockdown on the in vitro capacity 
of established and primary GBM cell lines to invade. We found that knockdown of the gene 
significantly (p<0.05 t-test) reduced the number of U251 and GIN17 GBM cells invading through the 
collagen barrier compared to untransfected or control siRNA cells (Figure 5 A-D).  
TM5441 is a potent and specific inhibitor of SERPINE1, which is bioavailable after oral 
administration. It has been noted to have cardioprotective effects but without the hemorrhagic 
complications associated with other SERPINE1 inhibitors
19
, but has not been investigated as a 
possible repurposed GBM treatment. Upon administration of TM5441 to the transwell assay, 
significant reduction (p<0.05 t-test) in the number of migrating cells was observed (Figure 5 E-G) 
even after controlling for reduction in cell numbers due to the anti-proliferative effect of TM5441 
(Supplementary Figure 5 E&F). A second, less specific SERPINE1 inhibitor (Tiplaxtinin) had a 
similar effect on viability but no significant effect on invasion after controlling for the decrease in cell 
viability (Supplementary Figure 5 G-I). 
 
Confirmation of 5ALA/FACS positive tumorigenicity in vivo 
To confirm that 5-ALA positive cells isolated from the resected GBM invasive tissue margin by 
FACS, represented a sub-population enriched for tumour cells, multiple subcutaneous xenograft 
implants were performed using different regions from resected primary tumor. No tumor uptake was 
evident in any animal injected with 5ALA/FACS negative cells after ~200 days. Animals with mixed 
unsorted invasive margin or core cell injections all grew visible tumors by the 200-day mark, whereas 
both animals injected with 5ALA/FACS positive cells grew tumors requiring sacrifice at 138- and 
145-days post-implant respectively (Figure 6A). 5ALA/FACS negative injections (green line) did not 
generate a subcutaneous tumor (the green line near the x-y axis intersection represents a minimal 
cubic volume caused by the injection of 5ALA/FACS negative cells, which subsequently did not 
engraft and proliferate).  The number of animals in this study are insufficient to establish whether 
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tumor uptake rate (and therefore tumor aggressiveness) in 5ALA/FACS is significantly greater than 
uptake rate for unsorted invasive margin and core tumor cells. 
 
A 5ALA/FACS positive tumor was serially transplanted into secondary recipients on day 145, with an 
increased rate (approximately double) of tumor uptake evident (69 days to reach tumor diameter of 
7.2 mm, relative to 119 days for a 6.8 mm diameter tumor in the primary recipient) (Supplementary 
Figure 6D). Based on standard histological staining, the 5ALA/FACS positive tumor xenograft 
closely resembled the primary GBM from which it was derived (Figure 6 B-C). Furthermore, 
immunohistochemical analysis of the tumor xenograft generated from 5ALA/FACS positive cells 
revealed a mitotically active (Ki67 positive) tumor, negative for the smooth muscle marker reticulin, 
but positive for glial fibrillary acidic protein (GFAP) (astrocytic marker) and vimentin (mesenchymal 
marker), collectively confirming glial and tumor origin of the xenograft from 5ALA positive GBM 
cells (Figure 6 D-F). 
 
Discussion 
The causes of the failure of molecularly targeted phase 3 trials and the high levels of treatment 
resistance exhibited by GBM are multifactorial, including innate upregulation of resistance associated 
genes, failure of drugs to achieve therapeutic concentrations within the tumor microenvironment and 
the capacity of GBM cells to rapidly adapt to the selection pressures. A key component of treatment 
resistance is the highly heterogeneous nature of individual GBMs, where diverse sub-clonal cell 
populations are present at each stage of disease progression
20
 and microenvironment
21
. Studies have 
shown that heterogeneity extends to a single cell level
8
 and exists on epigenetic, genetic and 
transcriptional levels
22
 with important consequences for properties such as temozolomide resistance, 
the first line standard of care agent for GBM
23
.  
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The current study sought to characterize heterogeneity on an intra-regional level and assess whether 
there is a consistent molecular pattern in differing tumor regions. Our particular focus was the 
invasive GBM cells migrating into the brain parenchyma, as this tumor sub-population most closely 
reflects residual disease which cannot be removed safely by surgery. We have isolated these cells 
using a novel 5ALA metabolism based method which is more inclusive of the totality of the tumor 
cell population(s) than previous attempts to study this population(s) based on subclonal genetic 
markers, e.g. EGFRVIII. We present, to the best of our knowledge, the first comprehensive RNAseq 
study of purified invasive GBM cells isolated in situ from patients. Our findings demonstrate that 
there is a specific molecular signature for this cell population with clear distinction from normal brain. 
The fluorescence positive cells are also different to the bulk tumor (core and rim) that has been 
traditionally studied in most previous comprehensive genome wide analyses
24
. We show that the 
invasive tumor cell population is tumorigenic, recapitulating fully the histological heterogeneity of the 
parent GBM. 
 
In our study, proliferation and migration/invasion were broadly dichotomous with core and rim cells 
displaying highly proliferative genotypes. In contrast many of these pathways were only expressed at 
low levels in the purified invasive cells, with far stronger representation of genes and pathways 
associated with ECM interaction, invasion and cell motility. Our findings demonstrate support for the 
„grow versus go‟ hypothesis in situ in primary GBM, albeit based on a presumably transient 
molecular snapshot at a particular disease stage. Previous studies examining a limited set of markers 
have suggested this phenomenon occurring in GBM cells with differing sets of transcription factors 
activated in migrating versus migration restricted cells
25
. Our unsupervised analysis demonstrates the 
differential activation of pathways in the clinical setting. One specific target we identify is the 
SERPINE1 gene (also known as plasminogen activator inhibitor 1 (PAI-1)). This gene is highly 
expressed in the 5ALA positive invasive GBM cell population in comparison to the 5ALA negative 
population. Previous analysis of TCGA genomic data has shown high SERPINE1 expression in many 
GBMs and a correlation between expression level and overall survival
26
. SERPINE1 expression is also 
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significantly different between the circumscribed grade I pilocytic astrocytoma and grade IV GBM
27
. 
SERPINE1 has diverse previously described roles including a possible function in 
immunomodulation
26
 and growth factor degradation
28
.  Here we show a non-canonical role in 
enhancing the invasive ability of GBM cells, but with no effect on cellular proliferation.  Our findings 
are consistent with a previous report of SERPINE1 involvement in the plasmin related degradation of 
ECM to allow invasion
27
 and with broader relevance as a possible doxorubicin resistance mechanism 
in breast cancer by preventing cellular senescence
28
. Pharmacological inhibition of SERPINE1 in mice 
or heterozygosity for the null allele in humans are both associated with cellular genetic integrity
29
. 
Specific pharmacological inhibitors of SERPINE1 have been developed and used in humans for 
hypertension and anti-thrombosis. Clinical trials were discontinued due to excess bleeding events but 
interestingly, genetically heterozygotic human populations do not display excess hemorrhage, 
suggesting controlled reduction in levels may be tolerable
29
.  
 
In conclusion, we demonstrate a unique expression profile on RNAseq for an invasive GBM cell 
population isolated on the basis of 5ALA induced fluorescence from amongst the predominant non-
neoplastic parenchyma in the invasive zone of GBM. This population appears to have reduced 
proliferation levels but exhibits significant upregulation of genes associated with invasion and 
migration. We suggest that future investigation of the 5ALA/FACS positive invasive cell population 
in bigger cohorts will yield further molecular markers that are specifically altered in the residual cell 
population that gives rise to GBM recurrence. Interrogation of this most clinically relevant population 
may lead to more appropriately and more effectively targeted precision therapy for patients with 
malignant brain tumors, with a methodological pipeline for isolation of invasive cells, potentially 
applicable for other solid cancers such as malignant breast tumors. 
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Figure Captions 
 
Figure 1 
 
An overview of 5aminolevulinic acid (5ALA) (Gliolan) guided surgery and sampling technique, 
showing: A – Conventional white light view through operating microscope of temporal lobe with 
partially resected GBM B – Same view under blue light demonstrating areas of 5ALA induced pink 
tumor fluorescence C – Metabolic pathway for fluorescent protoporphyrin IX synthesis in GBM cells 
after exogenous administration of 5ALA D – Representative image of multi-region surgical sampling 
from a GBM indicating typical sample locations 
 
Figure 2 
 
Administration of 5ALA, to cell lines and in fluorescent assisted cell sorting (FACS): A&C – U251 
GBM cells imaged with bright field microscopy (A) and fluorescence microscopy after administration 
of 5ALA (C) showing fluorescence in the vast majority of cells (scale bar 50µm). B&D – GIN17 
primary low passage GBM cells imaged with bright field microscopy (B) and fluorescence 
microscopy (D) after administration of 5ALA with near universal fluorescence (scale bar 50µm). E-H 
- Bright field (E&F) and fluorescence (G&H) microscopy of human neural cell stem cells in 
undifferentiated state (E&G) and after differentiation to astrocytes (F&H) with significantly reduced 
5ALA induced fluorescence in their differentiated state. I&J – FACS profile of a 50:50 mixture of 
5ALA treated/untreated U251 cells demonstrating clear separation of unexposed cells (left hand peak) 
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from cells exposed to 5ALA (right hand peak). K&L – Primary tumor specimens from patients 
undergoing isolation for 5ALA fluorescence positive tumor cells, demonstrating first stage 
enrichment, followed by purification on second sort. 
 
Figure 3 
 
RNAseq bioinformatics results. A – Heat map of RNAseq data demonstrating differentially expressed 
genes (p value <0.05 after multiple test correction) patterns between core/rim and invasive margin 
regions. B – Heatmap of RNAseq data showing differential expressed (p value <0.05 after multiple 
test correction) genes between 5ALA positive and 5ALA negative cells isolated from the invasive 
tumor regions. C – Heatmap showing differentially expressed genes (p value <0.05 after multiple test 
correction) between 5ALA positive cells (Pos) and unsorted mixed tumor regions from core, rim and 
invasive margin. D – Venn diagram of numbers of genes differentially over (top number) and under 
(bottom number) expressed between intra-tumor regions and 5ALA positive cells from invasive 
region. E – Examples of expression patterns of significantly differentially expressed genes of interest 
(VEGFa and MMP19), comparisons with asterix with p value <0.05, demonstrating significantly 
reduced expression levels of VEGFa in the invasive regions compared to core and rim and 
significantly elevated levels of MMP19 in the invasive regions and in particular in 5ALA positive 
cells. 
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Figure 4 
 
Expression levels of genes and proteins of interest in tumor and FACS isolated samples. A – 
Expression profiles across tumor regions and in 5ALA positive cells for selected genes demonstrating 
expression patterns varying in the unsorted invasive region and particularly in 5ALA positive cells 
isolated by FACS. B&C – Immunohistochemistry for VEGFa (x40 images) for a core (B) and 
invasive area (C) from the same GBM demonstrating representative high and low expression of 
VEGFa respectively D - RNAseq expression profiles for the PDL1 immune checkpoint molecule; 
showing high PDL1 expression in the tumor core and low expression in 5ALA positive invasive cells 
(p<0.05 T test, indicated by asterix). E&F – Immunohistochemistry for SERPINE1 images (x40 
images) showing high SERPINE1 expression in the tumor core (E) and overall low expression in the 
invasive zone (F); occasional positive cells in the invasive region (arrowhead) are hypothesized to be 
invasive GBM cells (magnified view of individual positive cell as insert). G – Expression levels on 
RNAseq of SERPINE1 in unsorted core, rim and invasive tumor areas and 5ALA positive and 
negative invasive cells, with elevated expression in the 5ALA positive FACS isolated population 
(significance compared to 5ALA negative cells  t test p=0.014, indicated by asterix). 
 
Figure 5 
 
Effects on GBM invasion upon siRNA-mediated post-transcriptional inhibition of SERPINE1 in vitro. 
A&B – Average number of invading U251 (A) and GIN17 (B) GBM cells per mm2 after 24 hours in 
the transwell plate in untreated controls with 0-1% FBS, 10% FBS, control siRNA transfection (10% 
FBS) or SERPINE1 siRNA transfection (10% FBS) (asterix indicates significant reduction (p<0.05 t-
test) in migrating cells between control siRNA and SERPINE1 targeting siRNA for U251 (A) and 
GIN17 (B). C&D – x40 images of U251 cells with control siRNA transfection (C) and SERPINE1 
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siRNA transfection (D) on transwell collagen invasion assay. E - Average number of invading GIN17 
GBM cells per mm
2
 of the transwell plate upon 24 hours exposure to 100µM and 200µM TM5441 
(SERPINE1 inhibitor) compared to controls with 0%, 1% and 10% serum in lower chamber and with 
DMSO control, showing significant reduction with the inhibitor (P<0.05 t-test, indicated by asterix). 
F&G – x40 images of GIN17 cells with 10%FBS control (F) or TM5441 200µM (G) showing number 
of cells visible on the transwell collagen invasion assay. 
 
Figure 6 
 
In vivo growth and immunohistochemistry. A – Relative growth rates over time since implantation of 
mixed unsorted (invasive margin or tumor core) cell xenografts (blue and purple lines), 5ALA/FACS 
negative cells (with no measurable tumor after day 20) (green lines) and 5ALA/FACS positive 
invasive cells (red line), showing no growth for 5ALA/FACS negative cells and quicker growth for 
5ALA/FACS positive compared to unsorted mixed cells. B – H&E of patient GBM (x40) from which 
a 5ALA/FACS positive xenograft was derived. C – H&E of a flank xenograft in mouse, 
demonstrating GBM-like morphology. D – Positive GFAP (astrocytic marker) IHC for mouse 
5ALA/FACS positive GBM xenograft. E – Positive IHC for Ki67 (proliferative marker) for mouse 
flank 5ALA/FACS positive GBM xenograft. F – Positive IHC for vimentin (mesenchymal marker) in 
mouse 5ALA/FACS positive GBM xenograft (all scale bars 100m). 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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